Vacuna contra el papilomavirus humano: actitud ante una consulta sobre una novedad terapéutica

Mintzes, 2006, Disease mongering in drug promotion: do governments have a regulatory role?, PLoS Med, 3, e198, 10.1371/journal.pmed.0030198 Gardasil. European public assessment report. Scientific discussion [citado 7 Mar 2007]. Disponible en: www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/070306en6.pdf Pichon-Rivière A, Augustovski F, Alcaraz A, Bardach A, Colantonio L, García S, et al. Eficacia de la vacuna para el virus del papiloma humano (HPV). Buenos Aires: Instituto de Efectividad Clínica y Sanitaria. Documentos de evaluación de tecnologías sanitarias. Informe de respuesta rápida 86. 2006 Oct [citado 7 Mar 2007]. Disponible en: www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=510 Schmiedeskamp, 2006, Human papillomavirus vaccines, Ann Pharmacother, 40, 1344, 10.1345/aph.1G723 2006, American College of Obstetricians and Gynecologists Committee Opinion No. 344. Human papillomavirus vaccination, Obstet Gynecol, 108, 699, 10.1097/00006250-200609000-00047 2007, Recommended immunization schedules for children and adolescents–United States, 2007, Pediatrics, 119, 207, 10.1542/peds.2006-3309 Harper DM. Human papillomavirus vaccines. UpToDate Online 15.1.Waltham (MA): UpToDate (Estados Unidos). C2007 [actualizado 8 Sep 2006; citado 7 Mar 2007]. Disponible en: www.utdol.com Villa, 2005, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol, 6, 271, 10.1016/S1470-2045(05)70101-7 Villa, 2006, Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18, Vaccine, 24, 5571, 10.1016/j.vaccine.2006.04.068 Mao, 2006, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstet Gynecol, 107, 18, 10.1097/01.AOG.0000192397.41191.fb Villa, 2006, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, Br J Cancer, 95, 1459, 10.1038/sj.bjc.6603469 Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. 2006 Jun [citado 7 Mar 2007]. Disponible en: www.cdc.gov/nip/recs/provisional_recs/hpv.pdf 2007, Statement on human papillomavirus vaccine, Can Commun Dis Rep, 33, 1 2007, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, N Engl J Med, 356, 1915, 10.1056/NEJMoa061741 Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, N Engl J Med, 356, 1928, 10.1056/NEJMoa061760 Markowitz, 2007, Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization and Practices (ACIP), MMWR Recomm Rep, 56, 1 Hunter MI, Holschneider CH. Cervical intraepithelial neoplasia: Etiology, diagnosis, and natural history. UpToDate Online 15.1. Waltham (MA): UpToDate (Estados Unidos). C2007 [actualizado 20 Oct 2006; citado 7 Mar 2007]. Disponible en: www.utdol.com Schiffman, 2005, The promise of global cervical-cancer prevention, N Engl J Med, 353, 2101, 10.1056/NEJMp058171 Spier, 1998, Ethical aspects of vaccines and vaccination, Vaccine, 16, 1788, 10.1016/S0264-410X(98)00169-8 Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004 [citado 7 Mar 2007]. Disponible en: www-dep.iarc.fr Marzo-Castillejo, 2005, Grupo de Prevención del Cáncer del PAPPS. Actualizaciones 2005, Aten Primaria, 36, S47 Pass, 1988, Vaccines for latent viruses, J Am Acad Dermatol, 18, 224, 10.1016/S0190-9622(88)70033-X Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74